{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:06Z","timestamp":1761894546104},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/s11864-004-0015-5","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T08:39:28Z","timestamp":1183019968000},"page":"239-247","source":"Crossref","is-referenced-by-count":36,"title":["Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1007","volume":"5","author":[{"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","volume":"117","author":"J Waldenstr\u00f6m","year":"1944","unstructured":"Waldenstr\u00f6m J: Incipient myelomatosis or \u201cessential\u201d hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med Scand 1944, 117:216\u2013222.","journal-title":"Acta Med Scand"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835\u20133849.","journal-title":"J Clin Oncol"},{"key":"15_CR3","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood.V83.12.3647.3647","volume":"83","author":"S Wagner","year":"1994","unstructured":"Wagner S, Martinelli V, Luzzato L: Similar patterns of somatic hypermutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstr\u00f6m\u2019s macroglobulinemia and myeloma. Blood 1994, 83:3647\u20133653.","journal-title":"Blood"},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2000.18.1.214","volume":"18","author":"MA Dimopoulos","year":"2000","unstructured":"Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al.: Waldenstr\u00f6m\u2019s macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000, 18:214\u2013226.","journal-title":"J Clin Oncol"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","volume":"115","author":"R. Garcia-Sanz","year":"2001","unstructured":"Garcia-Sanz, R., Montoto S, Torrequebrada A, et al.: Waldenstr\u00f6m macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001, 115:575\u2013582. This is a report of 217 patients presenting with WM in Spain over 10 years. It presents the clinical features, the prognostic factors, the treatments received, and the causes of death of these patients.","journal-title":"Br J Haematol"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1926::AID-CNCR9>3.0.CO;2-L","volume":"80","author":"JA Andriko","year":"1997","unstructured":"Andriko JA, Aguilera NS, Chu WS, et al.: Waldenstr\u00f6m\u2019s macroglobulinemia: a clinicopathologic study of 22 cases. Cancer 1997, 80:1926\u20131935.","journal-title":"Cancer"},{"key":"15_CR7","first-page":"104","volume":"36","author":"G Pangalis","year":"1999","unstructured":"Pangalis G, Angelopoulou M, Vassilakopoulos P: Bchronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstr\u00f6m\u2019s macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 1999, 36:104\u2013114.","journal-title":"Semin Hematol"},{"key":"15_CR8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)65225-2","volume":"62","author":"RA Kyle","year":"1987","unstructured":"Kyle RA, Garton JP: The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987, 62:719\u2013731.","journal-title":"Mayo Clin Proc"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346:564\u2013569. Monoclonal gammopathy of undetermined significance progressed in 115 of 1384 patients to MM, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma. This is the largest follow-up study of patients with MGUS.","journal-title":"N Engl J Med"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","volume":"10","author":"MA Gertz","year":"1995","unstructured":"Gertz MA, Kyle RA: Hyperviscosity syndrome. J Intensive Care 1995, 10:128\u2013141.","journal-title":"J Intensive Care"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1365-2141.2000.01918.x","volume":"108","author":"RA Kyle","year":"2000","unstructured":"Kyle RA, Greipp PR, Gertz MA, et al.: Waldenstr\u00f6m\u2019s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000, 108:737\u2013742. Seventy-nine percent of 24 patients administered continuous therapy had an objective improvement by reduction of serum M protein or increase in hemoglobin. Sixty-eight percent of 22 patients administered chlorambucil intermittently had an objective response. This is one of the most important studies showing effectiveness of chlorambucil in patients with WM.","journal-title":"Br J Haematol"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909109032794","volume":"9","author":"DC Case","year":"1991","unstructured":"Case DC Jr, Ervin TJ, Boyd MA, et al.: Waldenstr\u00f6m\u2019s macroglobulinemia: long-term results with the M-2 protocol. Cancer Invest 1991, 9:1\u20137.","journal-title":"Cancer Invest"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6690195","volume":"79","author":"FM Laurencet","year":"1999","unstructured":"Laurencet FM, Zulian GB, Guetty-Alberto M, et al.: Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999, 79:1215\u20131219.","journal-title":"Br J Cancer"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.V98.1.41","volume":"98","author":"MV Dhodapkar","year":"2001","unstructured":"Dhodapkar MV, Jacobson JL, Gertz MA, et al.: Prognostic factors and response to fludarabine therapy in patients with Waldenstr\u00f6m macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001, 98:41\u201348. One hundred eighty-two patients with symptomatic or progressive disease were treated with four to eight cycles of therapy with fludarabine. The overall rate of response to therapy was 36%, with 2% complete remission. Patients who were 70 years or older had a substantially lower likelihood of response.","journal-title":"Blood"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","volume":"118","author":"MA Dimopoulos","year":"1993","unstructured":"Dimopoulos MA, Kantarjian H, Estey E, et al.: Treatment of Waldenstr\u00f6m macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993, 118:195\u2013198.","journal-title":"Ann Intern Med"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1023\/A:1008350208019","volume":"10","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, White CA, Link B, et al.: Rituximab therapy in Waldenstr\u00f6m\u2019s macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999, 10:1525\u20131527.","journal-title":"Ann Oncol"},{"key":"15_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/00002371-200105000-00012","volume":"24","author":"SP Treon","year":"2001","unstructured":"Treon SP, Agus DB, Link B, et al.: CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. J Immunother 2001, 24:272\u2013279.","journal-title":"J Immunother"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","volume":"20","author":"MA Dimopoulos","year":"2002","unstructured":"Dimopoulos MA, Zervas C, Zomas A, et al.: Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab. J Clin Oncol 2002, 20:2327\u20132333. This is a prospective phase II study to define the activity of rituximab in patients with WM. Responses occurred in 40% of previously untreated patients and 50% of pretreated patients.","journal-title":"J Clin Oncol"},{"issue":"Suppl 12","key":"15_CR19","first-page":"79","volume":"27","author":"SP Treon","year":"2000","unstructured":"Treon SP, Anderson KC: The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000, 27(Suppl 12):79\u201385.","journal-title":"Semin Oncol"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 2002, 20:2453\u20132463.","journal-title":"J Clin Oncol"},{"key":"15_CR21","volume-title":"Blood: Atlas and Sourcebook of Hematology","author":"C Kapff","year":"1991","unstructured":"Kapff C, Jandl J: Blood: Atlas and Sourcebook of Hematology. Boston: Little Brown; 1991."},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jnci\/22.5.887","volume":"22","author":"T Dutcher","year":"1959","unstructured":"Dutcher T, Fahey J: The histopathology of macroglobulinemia of Waldenstr\u00f6m. J Natl Cancer Inst 1959, 22:887\u2013917.","journal-title":"J Natl Cancer Inst"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-0609.1983.tb00664.x","volume":"31","author":"R Bartl","year":"1983","unstructured":"Bartl R, Frisch B, Mahl G, et al.: Bone marrow histology in Waldenstr\u00f6m\u2019s macroglobulinaemia. Clinical relevance of subtype recognition. Scand J Haematol 1983, 31:359\u2013375.","journal-title":"Scand J Haematol"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/1099-1069(200006)18:2<41::AID-HON654>3.0.CO;2-W","volume":"18","author":"R Owen","year":"2000","unstructured":"Owen R, Johnson S, Morgan G: Waldenstr\u00f6m\u2019s macroglobulinemia: laboratory diagnosis and treatment. Hematol Oncol 2000, 18:41\u201349.","journal-title":"Hematol Oncol"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1309\/4LCN-JMPG-5U71-UWQB","volume":"116","author":"RG Owen","year":"2001","unstructured":"Owen RG, Barrans SL, Richards SJ, et al.: Waldenstr\u00f6m macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001, 116:420\u2013428.","journal-title":"Am J Clin Pathol"},{"key":"15_CR26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.1987.tb04139.x","volume":"65","author":"M Kucharska-Pulczynska","year":"1987","unstructured":"Kucharska-Pulczynska M, Ellegard J, Hokland P: Analysis of leukocyte differentiation antigens in blood and bone marrow from patients with Waldenstr\u00f6m macroglobulinemia. Br J Haematol 1987, 65:395\u2013399.","journal-title":"Br J Haematol"},{"key":"15_CR27","first-page":"348","volume":"3","author":"H Feiner","year":"1990","unstructured":"Feiner H, Rizk C, Finfer M: IgM monoclonal gammopathy\/ Waldenstr\u00f6m\u2019s macroglobulinemia: a morphological and immunophenotypic study of the bone marrow. Mod Pathol 1990, 3:348\u2013356.","journal-title":"Mod Pathol"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ajh.2830370221","volume":"37","author":"M Nagai","year":"1991","unstructured":"Nagai M, Ikeda K, Nakamura H, et al.: Splenectomy for a case with Waldenstr\u00f6m macroglobulinemia with giant splenomegaly. Am J Hematol 1991, 37:140.","journal-title":"Am J Hematol"},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ajh.2830480411","volume":"48","author":"JS Humphrey","year":"1995","unstructured":"Humphrey JS, Conley CL: Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am J Hematol 1995, 48:262\u2013266.","journal-title":"Am J Hematol"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2141.1995.tb05312.x","volume":"91","author":"AJ Winter","year":"1995","unstructured":"Winter AJ, Obeid D, Jones EL: Long survival after splenic immunoblastic transformation of Waldenstr\u00f6m\u2019s macroglobulinaemia. Br J Haematol 1995, 91:412\u2013414.","journal-title":"Br J Haematol"},{"key":"15_CR31","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.2001.19.16.3596","volume":"19","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zomas A, Viniou NA, et al.: Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with thalidomide. J Clin Oncol 2001, 19:3595\u20133601.","journal-title":"J Clin Oncol"},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1046\/j.1365-2141.1999.01461.x","volume":"105","author":"R Desikan","year":"1999","unstructured":"Desikan R, Dhodapkar M, Siegel D, et al.: High-dose therapy with autologous haemopoietic stem cell support for Waldenstr\u00f6m\u2019s macroglobulinaemia. Br J Haematol 1999, 105:993\u2013996.","journal-title":"Br J Haematol"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2141.1999.01493.x","volume":"106","author":"P Dreger","year":"1999","unstructured":"Dreger P, Glass B, Kuse R, et al.: Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstr\u00f6m\u2019s macroglobulinaemia. Br J Haematol 1999, 106:115\u2013118.","journal-title":"Br J Haematol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-004-0015-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0015-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-004-0015-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T13:17:20Z","timestamp":1652620640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-004-0015-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11864-004-0015-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}